199 related articles for article (PubMed ID: 29937926)
1. Copy number variation and high expression of DNA topoisomerase II alpha predict worse prognosis of cancer: a meta-analysis.
Ren L; Liu J; Gou K; Xing C
J Cancer; 2018; 9(12):2082-2092. PubMed ID: 29937926
[No Abstract] [Full Text] [Related]
2. Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy.
O'Malley FP; Chia S; Tu D; Shepherd LE; Levine MN; Bramwell VH; Andrulis IL; Pritchard KI
J Natl Cancer Inst; 2009 May; 101(9):644-50. PubMed ID: 19401546
[TBL] [Abstract][Full Text] [Related]
3. Predictive value of topoisomerase II alpha protein for clinicopathological characteristics and prognosis in early breast cancer.
Wu Y; Han Y; Li Q; Zhang P; Yuan P; Luo Y; Fan Y; Chen S; Cai R; Li Q; Xu H; Wang Y; Ma F; Wang J; Xu B
Breast Cancer Res Treat; 2022 Jun; 193(2):381-392. PubMed ID: 35297009
[TBL] [Abstract][Full Text] [Related]
4. High Ki-67 Immunohistochemical Reactivity Correlates With Poor Prognosis in Bladder Carcinoma: A Comprehensive Meta-Analysis with 13,053 Patients Involved.
Luo Y; Zhang X; Mo M; Tan Z; Huang L; Zhou H; Wang C; Wei F; Qiu X; He R; Chen G
Medicine (Baltimore); 2016 Apr; 95(15):e3337. PubMed ID: 27082587
[TBL] [Abstract][Full Text] [Related]
5. retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group.
Knoop AS; Knudsen H; Balslev E; Rasmussen BB; Overgaard J; Nielsen KV; Schonau A; Gunnarsdóttir K; Olsen KE; Mouridsen H; Ejlertsen B;
J Clin Oncol; 2005 Oct; 23(30):7483-90. PubMed ID: 16234514
[TBL] [Abstract][Full Text] [Related]
6. Multiplication of Chromosome 17 Centromere Is Associated with Prognosis in Patients with Invasive Breast Cancers Exhibiting Normal HER2 and TOP2A Status.
Kim A; Shin HC; Bae YK; Kim MK; Kang SH; Lee SJ; Lee EH
J Breast Cancer; 2012 Mar; 15(1):24-33. PubMed ID: 22493625
[TBL] [Abstract][Full Text] [Related]
7. Chromosome 17 centromere duplication and responsiveness to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Tibau A; López-Vilaró L; Pérez-Olabarria M; Vázquez T; Pons C; Gich I; Alonso C; Ojeda B; Ramón y Cajal T; Lerma E; Barnadas A; Escuin D
Neoplasia; 2014 Oct; 16(10):861-7. PubMed ID: 25379022
[TBL] [Abstract][Full Text] [Related]
8. Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer.
Arriola E; Rodriguez-Pinilla SM; Lambros MB; Jones RL; James M; Savage K; Smith IE; Dowsett M; Reis-Filho JS
Breast Cancer Res Treat; 2007 Dec; 106(2):181-9. PubMed ID: 17260090
[TBL] [Abstract][Full Text] [Related]
9. The value of TOP2A gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D.
Nielsen KV; Ejlertsen B; Møller S; Jørgensen JT; Knoop A; Knudsen H; Mouridsen HT
Acta Oncol; 2008; 47(4):725-34. PubMed ID: 18465341
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of topoisomerase 2A expression and gene change in operable invasive breast cancer.
Qiao JH; Jiao DC; Lu ZD; Yang S; Liu ZZ
Tumour Biol; 2015 Sep; 36(9):6833-8. PubMed ID: 25846735
[TBL] [Abstract][Full Text] [Related]
11. Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status.
Tubbs R; Barlow WE; Budd GT; Swain E; Porter P; Gown A; Yeh IT; Sledge G; Shapiro C; Ingle J; Haskell C; Albain KS; Livingston R; Hayes DF
J Clin Oncol; 2009 Aug; 27(24):3881-6. PubMed ID: 19620488
[TBL] [Abstract][Full Text] [Related]
12. Association between LKB1 expression and prognosis of patients with solid tumours: an updated systematic review and meta-analysis.
Ren YH; Zhao FJ; Mo HY; Jia RR; Tang J; Zhao XH; Wei JL; Huo RR; Li QQ; You XM
BMJ Open; 2019 Aug; 9(8):e027185. PubMed ID: 31383697
[TBL] [Abstract][Full Text] [Related]
13. DNMT3A R882 Mutations Predict a Poor Prognosis in AML: A Meta-Analysis From 4474 Patients.
Yuan XQ; Peng L; Zeng WJ; Jiang BY; Li GC; Chen XP
Medicine (Baltimore); 2016 May; 95(18):e3519. PubMed ID: 27149454
[TBL] [Abstract][Full Text] [Related]
14. Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer.
Rody A; Karn T; Ruckhäberle E; Müller V; Gehrmann M; Solbach C; Ahr A; Gätje R; Holtrich U; Kaufmann M
Breast Cancer Res Treat; 2009 Feb; 113(3):457-66. PubMed ID: 18340528
[TBL] [Abstract][Full Text] [Related]
15. Prognostic role of E2F1 gene expression in human cancer: a meta-analysis.
Li J; Bi W; Lu F; Pan B; Xiong M; Nasifu L; Nie Z; He B
BMC Cancer; 2023 Jun; 23(1):509. PubMed ID: 37277745
[TBL] [Abstract][Full Text] [Related]
16. Lack of independent prognostic and predictive value of centromere 17 copy number changes in breast cancer patients with known HER2 and TOP2A status.
Nielsen KV; Ejlertsen B; Møller S; Jensen MB; Balslev E; Müller S; Knoop A; Mouridsen HT
Mol Oncol; 2012 Feb; 6(1):88-97. PubMed ID: 22153616
[TBL] [Abstract][Full Text] [Related]
17. Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial.
O'Malley FP; Chia S; Tu D; Shepherd LE; Levine MN; Huntsman D; Bramwell VH; Andrulis IL; Pritchard KI
Breast Cancer Res Treat; 2011 Jul; 128(2):401-9. PubMed ID: 21519837
[TBL] [Abstract][Full Text] [Related]
18. HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy.
Fountzilas G; Valavanis C; Kotoula V; Eleftheraki AG; Kalogeras KT; Tzaida O; Batistatou A; Kronenwett R; Wirtz RM; Bobos M; Timotheadou E; Soupos N; Pentheroudakis G; Gogas H; Vlachodimitropoulos D; Polychronidou G; Aravantinos G; Koutras A; Christodoulou C; Pectasides D; Arapantoni P
J Transl Med; 2012 Jan; 10():10. PubMed ID: 22240029
[TBL] [Abstract][Full Text] [Related]
19. Association between high body mass index and prognosis of patients with early-stage breast cancer: A systematic review and meta-analysis.
Li Z; Shen G; Shi M; Zheng Y; Guan Y; Xin Y; Wang M; Zhao F; Ren D; Zhao J
Cancer Pathog Ther; 2023 Jul; 1(3):205-215. PubMed ID: 38327841
[TBL] [Abstract][Full Text] [Related]
20. Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab.
Fountzilas G; Christodoulou C; Bobos M; Kotoula V; Eleftheraki AG; Xanthakis I; Batistatou A; Pentheroudakis G; Xiros N; Papaspirou I; Koumarianou A; Papakostas P; Bafaloukos D; Skarlos DV; Kalogeras KT
J Transl Med; 2012 Oct; 10():212. PubMed ID: 23092535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
